OutSee is a techbio startup that is defining the state of the art in genomic drug target discovery. Where current methods search for correlation between genetics and disease, our AI platform Nomaly searches for the causal biological mechanisms driving the disease.

So far, the techbio industry has its tunnel vision focused on the creation of binders. By applying our technology to target identification, we are transforming a fundamental but overlooked pillar of drug development.

About Metrion

Metrion Biosciences (‘Metrion’) is a UK-based, ion channel focused Contract Research Organisation (CRO) providing high-quality in vitro preclinical drug discovery and safety profiling services. From our headquarters at Granta Park, Cambridge, we support a global customer base with cardiac safety profiling, ion channel drug discovery screening, medicinal chemistry screening support, and neuroscience assay services.

Role Summary

About ARU:

At ImmuONE, our vision is to transform in vitro inhalation safety assessment by providing the best-in-class in vitro models and tailored in vitro services that most accurately predict in vivo outcomes. We have unique capabilities in the development and commercialisation of immunocompetent 2D and 3D in vitro models and assessments and work with the pharmaceutical, consumer product and chemical sectors globally to provide vital data on safety of new products and pharmacology and efficacy of new therapeutics.